A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions ...

Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter ...

The latest advancements in global biosimilar access include new treatments, strategic partnerships, and competitive market ...

A review of the safety of biosimilar DMARDs during pregnancy reveals critical evidence gaps and the need for informed clinical guidance.

The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.

Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access and affordability in critical therapeutic areas. In 2025, European, Asian, ...

Australia's adoption of etanercept biosimilars enhances access to rheumatoid arthritis treatments, maintaining treatment persistence and patient care quality. Although Australia has one of the highest ...

AVT06, a promising biosimilar to aflibercept (Eylea), shows comparable efficacy and safety for treating neovascular age-related macular degeneration (AMD), enhancing patient access. AVT06, a proposed ...

Number 5: The FDA has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars to receive the green light from the agency. The approvals, granted to ...